United States Biotechnology & Medical Research

PMV Pharmaceuticals Inc (PMVP)

Track

PMV Pharmaceuticals Inc. experienced notable insider trading activity, primarily involving divestments by OrbiMed Advisors LLC and various corporate executives. The most recent transactions occurred on October 23, 2025, featuring significant share sales. These patterns reflect ongoing liquidation efforts by major shareholders alongside planned disposals from leadership personnel throughout the preceding months.
Ticker: PMVP Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for PMV Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 23 Oct 2025
Value US$2,891,857.05 | Price 377.19 | Shares 72,992 (-22.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-27 2025-10-23 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
72,992 -22.9%
377.19
US$2,891,857 		72,992 -22.9% 377.19 US$2,891,857
2025-10-23 2025-10-23 PrS Proposed sale
2.6
OrbiMed Private Investments V, LP

Shareholder
91,080
125.08
US$3,149,154 		91,080 125.08 US$3,149,154
2025-09-12 2025-09-10 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
93,877 -26.3%
299.26
US$3,460,134 		93,877 -26.3% 299.26 US$3,460,134
2025-09-10 2025-09-10 PrS Proposed sale
2.6
OrbiMed Private Investments V, LP

Shareholder
2,283,654
1.60
US$3,653,846 		2,283,654 1.60 US$3,653,846
2025-07-03 2025-07-01 PlS Planned sale
Ticktin Robert

General Counsel & COO

Officer
23,151 -19.0%
1.06
US$24,651 		23,151 -19.0% 1.06 US$24,651
2025-07-03 2025-07-01 S Sale
3.1
Jalota Deepika

Chief Development Officer

Officer
33,065 -26.9%
1.06
US$35,198 		33,065 -26.9% 1.06 US$35,198
2025-07-03 2025-07-01 PlS Planned sale
Mack David Henry

President and CEO

Executive Director
58,411 -9.8%
1.06
US$62,179 		58,411 -9.8% 1.06 US$62,179
2025-07-03 2025-07-01 S Sale
1.2
Carulli Michael

Chief Financial Officer

Officer
28,249 -32.0%
1.06
US$30,077 		28,249 -32.0% 1.06 US$30,077
2024-09-12 2024-09-11 S Sale
3.1
Jalota Deepika

Chief Development Officer

Officer
7,218 -5.8%
1.50
US$10,853 		7,218 -5.8% 1.50 US$10,853
2024-09-12 2024-09-11 S Sale
1.2
Carulli Michael

Chief Financial Officer

Officer
2,891 -3.2%
1.50
US$4,347 		2,891 -3.2% 1.50 US$4,347
2023-11-24 2023-11-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
87,786 -100.0%
2.23
US$195,763 		87,786 -100.0% 2.23 US$195,763
2023-11-22 2023-11-22 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, L.P.

Shareholder
87,786
2.25
US$197,519 		87,786 2.25 US$197,519
2023-09-18 2023-09-15 S Sale
2.6
Alland Leila

Chief Medical Officer

Officer
6,291 -12.1%
6.62
US$41,646 		6,291 -12.1% 6.62 US$41,646
2023-09-18 2023-09-15 S Sale
3.1
Jalota Deepika

Chief Development Officer

Officer
4,104 -12.1%
6.62
US$27,168 		4,104 -12.1% 6.62 US$27,168
2022-05-31 2022-05-26 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
26,253 -23.0%
15.93
US$418,210 		26,253 -23.0% 15.93 US$418,210
2021-10-08 2021-10-06 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
800 -0.1%
30.15
US$24,120 		800 -0.1% 30.15 US$24,120
2021-10-04 2021-10-04 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
100 -0.0%
30.08
US$3,008 		100 -0.0% 30.08 US$3,008
2021-10-04 2021-10-01 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
11,541 -1.0%
30.10
US$347,384 		11,541 -1.0% 30.10 US$347,384
2021-10-04 2021-09-30 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
2,978 -0.3%
30.03
US$89,429 		2,978 -0.3% 30.03 US$89,429
2021-09-29 2021-09-29 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
5,708 -0.5%
30.04
US$171,468 		5,708 -0.5% 30.04 US$171,468
2021-09-29 2021-09-27 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
1,753 -0.2%
30.11
US$52,783 		1,753 -0.2% 30.11 US$52,783
2021-09-13 2021-09-13 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
13,272 -1.2%
30.20
US$400,814 		13,272 -1.2% 30.20 US$400,814
2021-09-13 2021-09-10 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
5,171 -0.5%
31.03
US$160,456 		5,171 -0.5% 31.03 US$160,456
2021-09-13 2021-09-10 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
38,056 -3.2%
30.44
US$1,158,425 		38,056 -3.2% 30.44 US$1,158,425
2021-09-13 2021-09-09 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
14,329 -1.2%
30.31
US$434,312 		14,329 -1.2% 30.31 US$434,312
2021-08-20 2021-08-19 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
3,800 -0.2%
30.97
US$117,686 		3,800 -0.2% 30.97 US$117,686
2021-08-20 2021-08-18 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
2,237 -0.1%
34.32
US$76,774 		2,237 -0.1% 34.32 US$76,774
2021-08-20 2021-08-18 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
13,196 -0.8%
33.84
US$446,553 		13,196 -0.8% 33.84 US$446,553
2021-08-20 2021-08-18 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
11,431 -0.7%
32.57
US$372,308 		11,431 -0.7% 32.57 US$372,308
2021-08-04 2021-08-03 PlS Planned sale
Kung Winston

COO, CFO

Officer
4,500 -73.8%
33.82
US$152,178 		4,500 -73.8% 33.82 US$152,178
2021-07-08 2021-07-08 PlS Planned sale
Kung Winston

COO, CFO

Officer
4,500 -73.8%
33.75
US$151,875 		4,500 -73.8% 33.75 US$151,875
2021-06-29 2021-06-28 PlS Planned sale
Mack David Henry

President and CEO

Executive Director
204 -1.6%
35.53
US$7,248 		204 -1.6% 35.53 US$7,248
2021-06-15 2021-06-14 S Sale
3.2
Euclidean Capital LLC
Large shareholder
1,260 -1.0%
34.11
US$42,979 		1,260 -1.0% 34.11 US$42,979
2021-06-15 2021-06-14 S Sale
3.2
Euclidean Capital LLC
Large shareholder
24,726 -1.0%
34.11
US$843,404 		24,726 -1.0% 34.11 US$843,404
2021-06-15 2021-06-14 S Sale
3.2
Euclidean Capital LLC
Large shareholder
7,141 -1.0%
34.11
US$243,580 		7,141 -1.0% 34.11 US$243,580
2021-06-15 2021-06-14 S Sale
3.2
Euclidean Capital LLC
Large shareholder
6,593 -1.0%
34.11
US$224,887 		6,593 -1.0% 34.11 US$224,887
2021-06-15 2021-06-14 S Sale
3.2
Euclidean Capital LLC
Large shareholder
4,699 -1.0%
34.11
US$160,283 		4,699 -1.0% 34.11 US$160,283
2021-06-15 2021-06-11 S Sale
3.2
Euclidean Capital LLC
Large shareholder
621 -0.5%
33.80
US$20,990 		621 -0.5% 33.80 US$20,990
2021-06-15 2021-06-11 S Sale
3.2
Euclidean Capital LLC
Large shareholder
12,237 -0.5%
33.80
US$413,611 		12,237 -0.5% 33.80 US$413,611
2021-06-15 2021-06-11 S Sale
3.2
Euclidean Capital LLC
Large shareholder
3,533 -0.5%
33.80
US$119,415 		3,533 -0.5% 33.80 US$119,415
2021-06-15 2021-06-11 S Sale
3.2
Euclidean Capital LLC
Large shareholder
3,262 -0.5%
33.80
US$110,256 		3,262 -0.5% 33.80 US$110,256
2021-06-15 2021-06-11 S Sale
3.2
Euclidean Capital LLC
Large shareholder
2,324 -0.5%
33.80
US$78,551 		2,324 -0.5% 33.80 US$78,551
2021-06-11 2021-06-10 S Sale
3.2
Euclidean Capital LLC
Large shareholder
585 -0.4%
32.68
US$19,118 		585 -0.4% 32.68 US$19,118
2021-06-11 2021-06-10 S Sale
3.2
Euclidean Capital LLC
Large shareholder
11,485 -0.5%
32.68
US$375,330 		11,485 -0.5% 32.68 US$375,330
2021-06-11 2021-06-10 S Sale
3.2
Euclidean Capital LLC
Large shareholder
3,317 -0.5%
32.68
US$108,400 		3,317 -0.5% 32.68 US$108,400
2021-06-11 2021-06-10 S Sale
3.2
Euclidean Capital LLC
Large shareholder
3,063 -0.5%
32.68
US$100,099 		3,063 -0.5% 32.68 US$100,099
2021-06-11 2021-06-10 S Sale
3.2
Euclidean Capital LLC
Large shareholder
2,183 -0.5%
32.68
US$71,340 		2,183 -0.5% 32.68 US$71,340
2021-06-11 2021-06-09 S Sale
3.2
Euclidean Capital LLC
Large shareholder
1,121 -0.9%
33.64
US$37,710 		1,121 -0.9% 33.64 US$37,710
2021-06-11 2021-06-09 S Sale
3.2
Euclidean Capital LLC
Large shareholder
22,070 -0.9%
33.64
US$742,435 		22,070 -0.9% 33.64 US$742,435
2021-06-11 2021-06-09 S Sale
3.2
Euclidean Capital LLC
Large shareholder
6,372 -0.9%
33.64
US$214,354 		6,372 -0.9% 33.64 US$214,354
2021-06-11 2021-06-09 S Sale
3.2
Euclidean Capital LLC
Large shareholder
5,883 -0.9%
33.64
US$197,904 		5,883 -0.9% 33.64 US$197,904
2021-06-11 2021-06-09 S Sale
3.2
Euclidean Capital LLC
Large shareholder
4,192 -0.9%
33.64
US$141,019 		4,192 -0.9% 33.64 US$141,019
2021-06-09 2021-06-08 S Sale
3.2
Euclidean Capital LLC
Large shareholder
896 -0.7%
33.38
US$29,908 		896 -0.7% 33.38 US$29,908
2021-06-09 2021-06-08 S Sale
3.2
Euclidean Capital LLC
Large shareholder
17,664 -0.7%
33.38
US$589,624 		17,664 -0.7% 33.38 US$589,624
2021-06-09 2021-06-08 S Sale
3.2
Euclidean Capital LLC
Large shareholder
5,101 -0.7%
33.38
US$170,271 		5,101 -0.7% 33.38 US$170,271
2021-06-09 2021-06-08 S Sale
3.2
Euclidean Capital LLC
Large shareholder
4,708 -0.7%
33.38
US$157,153 		4,708 -0.7% 33.38 US$157,153
2021-06-09 2021-06-08 S Sale
3.2
Euclidean Capital LLC
Large shareholder
3,355 -0.7%
33.38
US$111,990 		3,355 -0.7% 33.38 US$111,990
2021-06-09 2021-06-07 S Sale
3.2
Euclidean Capital LLC
Large shareholder
1,019 -0.8%
33.62
US$34,259 		1,019 -0.8% 33.62 US$34,259
2021-06-09 2021-06-07 S Sale
3.2
Euclidean Capital LLC
Large shareholder
16,901 -0.6%
33.62
US$568,212 		16,901 -0.6% 33.62 US$568,212
2021-06-09 2021-06-07 S Sale
3.2
Euclidean Capital LLC
Large shareholder
4,946 -0.7%
33.62
US$166,285 		4,946 -0.7% 33.62 US$166,285
2021-06-09 2021-06-07 S Sale
3.2
Euclidean Capital LLC
Large shareholder
4,564 -0.7%
33.62
US$153,442 		4,564 -0.7% 33.62 US$153,442
2021-06-09 2021-06-07 S Sale
3.2
Euclidean Capital LLC
Large shareholder
3,291 -0.7%
33.62
US$110,643 		3,291 -0.7% 33.62 US$110,643
2021-06-08 2021-06-07 PlS Planned sale
2.6
Alland Leila

Chief Medical Officer

Officer
1,367 -100.0%
34.00
US$46,484 		1,367 -100.0% 34.00 US$46,484
2021-06-08 2021-06-07 PlS Planned sale
2.6
Alland Leila

Chief Medical Officer

Officer
2,633 -65.8%
33.39
US$87,903 		2,633 -65.8% 33.39 US$87,903
2021-06-07 2021-06-04 PlS Planned sale
Kung Winston

COO, CFO

Officer
4,500 -73.8%
33.75
US$151,875 		4,500 -73.8% 33.75 US$151,875
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
2 -100.0%
34.67
US$69 		2 -100.0% 34.67 US$69
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
209 -99.1%
33.79
US$7,062 		209 -99.1% 33.79 US$7,062
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
764 -78.4%
32.15
US$24,563 		764 -78.4% 32.15 US$24,563
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
2 -100.0%
34.67
US$69 		2 -100.0% 34.67 US$69
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
230 -99.1%
33.75
US$7,762 		230 -99.1% 33.75 US$7,762
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
743 -76.2%
32.16
US$23,896 		743 -76.2% 32.16 US$23,896
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
5 -100.0%
34.67
US$173 		5 -100.0% 34.67 US$173
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
553 -99.1%
33.61
US$18,587 		553 -99.1% 33.61 US$18,587
2021-06-02 2021-06-01 PlS Planned sale
Heyman Richard A.
Non-Executive Director
1,392 -71.4%
32.15
US$44,754 		1,392 -71.4% 32.15 US$44,754
2021-06-02 2021-05-28 PlS Planned sale
2.1
Schroeder Thilo
Non-Executive Director
5,100 -0.2%
35.80
US$182,580 		5,100 -0.2% 35.80 US$182,580
Explore more

More insider trading research around PMV Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America